Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 274-386-6 | CAS number: 70209-87-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The oral LD50 for the substance was considered to be 1717 mg/kg bw.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- no data
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- Principles of method if other than guideline:
- not applicable
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Tif: RAIf (SPF)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Healthy random bred animals raised on the premises of the testing laboratory were used for the study. They were kept at a room temperature of 22±1 °C, at a relative humidity of 55±5 % and on a 10 h light cycle day. They received ad libitum rat food - NAFAG, Gossau SG - and water. Prior to treatment the animals were adapted to our laboratories for a minimum of 4 d and the initial body weight ranged from 160 to 180 g. During the treatment and observation period the animals were housed in groups of 5 in Macrolon cages (type 3). Animals were fasted overnight before treatment.
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Remarks:
- (PEG 400)
- Details on oral exposure:
- The test substance was suspended with PEG 400. Before treatment the suspension was homogeneously dispersed with an Ultra-Turrax and during treatment it was kept stable with a magnetic stirrer. The concentrations of the test substance in the vehicle were 5, 10, 10, and 30 % which correspond to the dose levels of 600, 1000, 2150 and 4640 mg/kg bw respectively.
- Doses:
- 600, 1000, 2150 and 4640 mg/kg bw
- No. of animals per sex per dose:
- 5/sex/dose
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 d
- Frequency of observations: Animals observed for mortality at 1, 24, and 48 h and weekly thereafter.
- Necropsy of survivors performed: Yes, animals were submitted at random to a necropsy whenever they died, survivors at the end of the observation period.
- Other examinations performed: clinical signs - Statistics:
- LD50 including 95 % confidence limits were calculated by the logit model.
- Preliminary study:
- not applicable
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 1 717 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 1 271 - 2 433
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 1 408 mg/kg bw
- Based on:
- act. ingr.
- Mortality:
- A dose dependent increase in the rate of mortality was observed. No mortality was noted at the lowest dose, 2 and 6 deaths were noted in the two subsequent intermediate dose levels respectively and the highest mortality of 10 animals was recorded at the highest dose level.
- Clinical signs:
- other: Within 2 h after treatment the animals in all dosage groups showed dyspnoea, curved position, diarrhoea and ruffled fur. With the exception of the animals in the lowest dose level, sedation was also observed. Diarrhoea became more accentuated as the dose
- Gross pathology:
- No test substance related gross organ changes were observed.
- Other findings:
- none
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The oral LD50 of the test substance was found to be 1717 (1271-2433) mg/kg bw (i.e. ca. 1408 mg a.i./kg bw)
- Executive summary:
A study was conducted to evaluate the acute oral toxicity of the test substance (at ca. 82 % purity) following a method comparable to OECD Guideline 401. Four groups of fasted Tif: RAI rats (5/sex/dose) received the test substance at 0, 600, 1000, 2150 and 4640 mg/kg bw once by oral intubation. Animals were observed for mortality and clinical signs for a period of 14 d. At the end of this period, animals were sacrificed and autopsied. No mortality was noted at the lowest dose, 2/10 and 6/10 animals died in the two subsequent intermediate dose levels and mortality of 10/10 animals was recorded at the highest dose level. All the animals across dose groups showed sedation (except lowest dose level), dyspnoea, curved position, diarrhoea and ruffled fur within 2 h of test substance administration. Diarrhoea became more pronounced with increment in dose. The surviving animals recovered within 9 -12 d. Under the study conditions, the oral LD50 of the test substance was found to be 1717 (1271-2433) mg/kg bw (i.e. ca. 1408 mg a.i./kg bw).
Reference
none
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 1 717 mg/kg bw
- Quality of whole database:
- Good quality study conducted according to acceptable methodology
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Acute toxicity: oral
Two studies on oral toxicity are availble:
In the first study acute oral toxicity of the test substance (at ca. 75 % purity) was evaluated following a method comparable to OECD Guideline 401. Four groups of fasted Tif: RAI rats (5/sex/dose) received the test substance at 1670, 2780, 3590 and 4640 mg/kg bw once by oral intubation. All the animals were observed for mortality and clinical signs for a period of 14 d.No mortality was noted at the lowest dose, 1/10 and 2/10 animals died in the two subsequent intermediate dose levels and mortality of 5/10 animals was recorded at the highest dose level. All the animals across dose groups showed sedation, dyspnoea, curved position, diarrhoea and ruffled fur within 2 h of test substance administration. Diarrhoea became more pronounced with increment in dose. The surviving animals recovered within 9 d. No test substance-related macroscopic changes were observed. Under the study conditions, the LD50 value of the test substance was 4706 (3602-6149) mg/kg bw (i.e. ca. 3530 mg a.i./kg bw).
In the second study, the acute oral toxicity of the test substance (at ca. 82 % purity) was evaluated following a method comparable to OECD Guideline 401. Four groups of fasted Tif: RAI rats (5/sex/dose) received the test substance at 0, 600, 1000, 2150 and 4640 mg/kg bw once by oral intubation. Animals were observed for mortality and clinical signs for a period of 14 d. At the end of this period, animals were sacrificed and autopsied. No mortality was noted at the lowest dose, 2/10 and 6/10 animals died in the two subsequent intermediate dose levels and mortality of 10/10 animals was recorded at the highest dose level. All the animals across dose groups showed sedation (except lowest dose level), dyspnoea, curved position, diarrhoea and ruffled fur within 2 h of test substance administration. Diarrhoea became more pronounced with increment in dose. The surviving animals recovered within 9 -12 d. Under the study conditions, the oral LD50 of the test substance was found to be 1717 (1271-2433) mg/kg bw (i.e. ca. 1408 mg a.i./kg bw).
Justification for selection of acute toxicity – oral endpoint
Two acute oral studies were conducted on rats using two different preparations of the test substance. In the first study, the LD50 value of the test substance was 4706 (3602-6149) mg/kg bw with a test item purity of 75 %. In the second study, the oral LD50 of the test substance was found to be 1717 (1271-2433) mg/kg bw with a test item purity of 82 %. As both studies were of similar quality (Klimisch 2), the lowest value was selected as the key value.
Acute toxicity: inhalation
The test substance has very low vapor pressure and high melting point (>260 °C), so the potential for the generation of inhalable forms is low. The low partition coefficient of -0.68 at 20 °C again point to poor absorption across the respiratory tract. The substance was found to have high water solubility (135 g/L), hence the inhaled dust may be retained within the mucus of the respiratory tract, thereby limiting absorption. Also the use of this substance will not result in aerosols, particles or droplets of an inhalable size, so exposure to humans via the inhalatory route will be unlikely to occur. Taking into consideration all above argumants, acute inhalation toxicity test was considered scientifically not neccessary.
Acute toxicity: dermal
Currently no study to assess acute dermal toxicity of Acid Red 315 is available. However, the molecular weight of the substance is 803.6 g/mol, which indicates the substance being too large for dermal absorption. Further, high water solubility (135 g/L) and low partition coefficient (-0.68 at 20 °C), indicate the substance may be too hydrophilic to cross the lipid rich environment of the stratum corneum. Hence, the dermal uptake for the substance is expected to be low. Absence of systemic toxicity in skin irritation as well as sensitization studies, further supports the conclusion that low toxicity is expected on acute dermal exposure of the target chemical and testing by the dermal route was considered scientifically not necessary.
Justification for classification or non-classification
Based on the available data (oral LD50= 1717 mg/kg bw), Acid Red 315 needs to be classsified as Acute Oral Toxicity Category 4 (H302) according to CLP (Regulation (EC) No 1272/2008 Of The European Parliament And Of The Council) as implementation of UN-GHS in the EU.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.